Arbutus Biopharma Corp [ABUS] stock prices are up 15.87% to $2.92 at the moment. An important factor to consider is whether the stock is rising or falling in short-term value. The ABUS shares have gain 17.27% over the last week, with a monthly amount glided 7.75%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Arbutus Biopharma Corp [NASDAQ: ABUS] stock has seen the most recent analyst activity on February 02, 2022, when Jefferies upgraded its rating to a Buy but kept the price target unchanged to $5 for it. Previously, Jefferies started tracking the stock with Hold rating on February 25, 2021, and set its price target to $5. On December 17, 2020, H.C. Wainwright initiated with a Buy rating and assigned a price target of $10 on the stock. Robert W. Baird downgraded its rating to a Neutral. Wedbush upgraded its rating to Outperform for this stock on May 19, 2020. In a note dated March 06, 2020, Chardan Capital Markets upgraded an Buy rating on this stock but restated the target price of $5.
The stock price of Arbutus Biopharma Corp [ABUS] has been fluctuating between $1.69 and $3.12 over the past year. Currently, Wall Street analysts expect the stock to reach $8.5 within the next 12 months. Arbutus Biopharma Corp [NASDAQ: ABUS] shares were valued at $2.92 at the most recent close of the market. An investor can expect a potential return of 191.1% based on the average ABUS price forecast.
Analyzing the ABUS fundamentals
The Arbutus Biopharma Corp [NASDAQ:ABUS] reported sales of 18.14M for trailing twelve months, representing a drop of -65.65%. Gross Profit Margin for this corporation currently stands at 0.92% with Operating Profit Margin at -4.29%, Pretax Profit Margin comes in at -4.02%, and Net Profit Margin reading is -3.97%. To continue investigating profitability, this company’s Return on Assets is posted at -0.5, Equity is -0.57 and Total Capital is -0.64. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.07.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 2.40 points at the first support level, and at 1.87 for the second support level. However, for the 1st resistance point, the stock is sitting at 3.35, and for the 2nd resistance point, it is at 3.77.
Ratios To Look Out For
It’s worth pointing out that Arbutus Biopharma Corp [NASDAQ:ABUS]’s Current Ratio is 5.87. On the other hand, the Quick Ratio is 5.87, and the Cash Ratio is 1.17. Considering the valuation of this stock, the price to sales ratio is 28.89, the price to book ratio is 4.68.
Transactions by insiders
Recent insider trading involved McElhaugh Michael J., Interim President & CEO, that happened on Feb 02 ’24 when 10164.0 shares were sold. Chief Scientific Officer, Sofia Michael J. completed a deal on Feb 02 ’24 to sell 9982.0 shares. Meanwhile, Chief Financial Officer HASTINGS DAVID C sold 9593.0 shares on Feb 02 ’24.
